AR114029A2 - Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos - Google Patents
Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesosInfo
- Publication number
- AR114029A2 AR114029A2 ARP180103297A ARP180103297A AR114029A2 AR 114029 A2 AR114029 A2 AR 114029A2 AR P180103297 A ARP180103297 A AR P180103297A AR P180103297 A ARP180103297 A AR P180103297A AR 114029 A2 AR114029 A2 AR 114029A2
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- useful
- amyloid deposits
- compounds
- processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 4
- 239000002243 precursor Substances 0.000 title abstract 4
- 208000037259 Amyloid Plaque Diseases 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FXERARHKNULYEN-HUYCHCPVSA-N 2-[6-(18F)fluoranyl-5-(methylamino)pyridin-2-yl]-1-benzofuran-5-ol Chemical compound [18F]C1=C(C=CC(=N1)C=1OC2=C(C=1)C=C(C=C2)O)NC FXERARHKNULYEN-HUYCHCPVSA-N 0.000 abstract 1
- ACZGCWSMSTYWDQ-UHFFFAOYSA-N 3h-1-benzofuran-2-one Chemical compound C1=CC=C2OC(=O)CC2=C1 ACZGCWSMSTYWDQ-UHFFFAOYSA-N 0.000 abstract 1
- -1 [6- (5-ethoxymethoxy-benzofuran-2-yl) -2-nitro-pyridin-3-yl] -methyl acid tert-butyl ester Chemical compound 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000011503 in vivo imaging Methods 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002600 positron emission tomography Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Furan Compounds (AREA)
Abstract
La presente se refiere a derivados que son adecuados como precursores de compuestos útiles para obtener imágenes de depósitos amiloides en pacientes vivos, a sus composiciones, a métodos de uso y a procesos para preparar dichos compuestos. Los compuestos que derivan de estos precursores son útiles en métodos de imaginología in vivo de depósitos amiloides en el cerebro para permitir el diagnóstico ante mortem de la enfermedad de Alzheimer mediante tomografía por emisión de positrones (PET) así como la medición de la eficacia clínica de agentes terapéuticos para la enfermedad de Alzheimer. Además, la presente también divulga los compuestos precursores en forma cristalina. Reivindicación 1: Un compuesto o una de sus sales, donde el compuesto es el éster terc-butílico del ácido [6-(5-etoximetoxi-benzofuran-2-il)-2-nitro-piridin-3-il]-metil-carbámico. Reivindicación 5: El compuesto o una de sus sales de acuerdo con la reivindicación 1, en una forma cristalina que comprende los picos de difracción siguientes: 11,27; 12,00; 13,51; 15,53; 16,82; 17,91; y 23,72 º2q. Reivindicación 8: El uso de acuerdo con la reivindicación 6 ó 7, donde el compuesto marcado es 2-(6-[¹⁸F]-flúor-5-metilamino-piridin-2-il)-benzofuran-5-ol o una de sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9285108P | 2008-08-29 | 2008-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114029A2 true AR114029A2 (es) | 2020-07-15 |
Family
ID=41721733
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103323A AR073230A1 (es) | 2008-08-29 | 2009-08-28 | Derivados del acido benzofuran-piridin carbamico, utiles en la preparacion de compuestos marcados, proceso para prepararlos y proceso para preparar precursores de sintesis. |
| ARP180103297A AR114029A2 (es) | 2008-08-29 | 2018-11-12 | Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103323A AR073230A1 (es) | 2008-08-29 | 2009-08-28 | Derivados del acido benzofuran-piridin carbamico, utiles en la preparacion de compuestos marcados, proceso para prepararlos y proceso para preparar precursores de sintesis. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8193363B2 (es) |
| EP (1) | EP2328891B1 (es) |
| JP (1) | JP5613669B2 (es) |
| KR (1) | KR101648848B1 (es) |
| CN (3) | CN104478862B (es) |
| AR (2) | AR073230A1 (es) |
| AU (1) | AU2009286176B2 (es) |
| BR (1) | BRPI0917147B8 (es) |
| CA (1) | CA2735497C (es) |
| CL (1) | CL2011000420A1 (es) |
| CO (1) | CO6341628A2 (es) |
| EA (1) | EA019093B1 (es) |
| EC (1) | ECSP11010850A (es) |
| ES (1) | ES2627769T3 (es) |
| IL (1) | IL211188A0 (es) |
| MX (1) | MX2011001918A (es) |
| NZ (1) | NZ591446A (es) |
| PE (1) | PE20110393A1 (es) |
| TW (1) | TW201014848A (es) |
| UY (1) | UY32076A (es) |
| WO (1) | WO2010024769A1 (es) |
| ZA (1) | ZA201102284B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193363B2 (en) | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
| JP5825608B2 (ja) * | 2010-08-06 | 2015-12-02 | 国立大学法人京都大学 | ピリジルベンゾフラン誘導体 |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| KR102053484B1 (ko) | 2012-12-21 | 2019-12-06 | 국립연구개발법인 양자과학기술연구개발기구 | 뇌 안에 축적된 타우 단백질을 이미징하기 위한 신규한 화합물 |
| US10913736B2 (en) | 2014-08-22 | 2021-02-09 | University Of Washington | Specific inhibitors of methionyl-tRNA synthetase |
| KR20180113975A (ko) * | 2015-11-20 | 2018-10-17 | 나비디아 바이오파마슈티컬즈, 인크. | 2-헤테로아릴 치환된 벤조푸란에 대한 제제 |
| JP2023502605A (ja) | 2019-11-13 | 2023-01-25 | アプリノイア セラピューティクス リミテッド | タウタンパク質凝集物を分解する化合物及びその使用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1041525A (en) | 1964-11-11 | 1966-09-07 | Belge Produits Chimiques Sa | Benzofuran derivatives and processes for preparing the same |
| CA2176127A1 (en) | 1993-12-21 | 1995-06-29 | William Henry Walker Lunn | Methods for the treatment or prevention of conditions associated with amyloidogenic reptides |
| DE60009116T2 (de) * | 1999-10-15 | 2005-02-17 | F. Hoffmann-La Roche Ag | Benzodiazepinderivate und deren verwendung als metabotrope glutamatrezeptor antagonisten |
| FR2800069A1 (fr) * | 1999-10-22 | 2001-04-27 | Centre Nat Rech Scient | 3-amino-2,2-di-c-alkyl-1,4-butyrolactones et 1,4- thiobutyrolactones n-substituees utiles comme stimulant de l'activite de l'acide gamma-aminobutyrique et leur procede de preparation |
| JP2004520347A (ja) | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| JP4307001B2 (ja) | 2001-03-14 | 2009-08-05 | キヤノン株式会社 | 金属配位化合物、電界発光素子及び表示装置 |
| GB0130305D0 (en) * | 2001-12-19 | 2002-02-06 | Amersham Plc | Compounds for imaging alzheimers disease |
| DE60326735D1 (de) | 2002-08-02 | 2009-04-30 | Genesoft Pharmaceuticals Inc | Biaryl-verbindungen mit antiinfektiver wirkung |
| EP1631561B1 (en) * | 2003-05-07 | 2010-08-18 | General Electric Company | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| US20040223912A1 (en) * | 2003-05-07 | 2004-11-11 | Montalto Michael Christopher | Compositions and methods for non-invasive imaging of soluble beta-amyloid |
| CA2530389A1 (en) | 2003-07-02 | 2005-01-13 | Biofocus Discovery Limited | Pyrazine and pyridine derivatives as rho kinase inhibitors |
| US7541357B2 (en) * | 2004-07-15 | 2009-06-02 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| EP2457901A1 (en) * | 2005-03-14 | 2012-05-30 | High Point Pharmaceuticals, LLC | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
| JP5121707B2 (ja) | 2005-07-04 | 2013-01-16 | ハイ ポイント ファーマシューティカルズ，エルエルシー | 新規医薬 |
| WO2007047204A1 (en) * | 2005-10-11 | 2007-04-26 | University Of Pittsburgh | Isotopically-labeled benzofuran compounds as imagingagents foramyloidogenic proteins |
| TW200736252A (en) * | 2006-01-27 | 2007-10-01 | Astrazeneca Ab | Novel heteroaryl substituted benzothiazoles |
| EP2113258A1 (en) * | 2006-12-05 | 2009-11-04 | Nagasaki University | Aurone derivative-containing composition for diagnosis |
| JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| TW200901998A (en) * | 2007-03-06 | 2009-01-16 | Astrazeneca Ab | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes |
| US8193363B2 (en) | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
-
2009
- 2009-08-20 US US12/544,556 patent/US8193363B2/en active Active
- 2009-08-27 UY UY0001032076A patent/UY32076A/es not_active Application Discontinuation
- 2009-08-27 TW TW098128873A patent/TW201014848A/zh unknown
- 2009-08-28 AU AU2009286176A patent/AU2009286176B2/en active Active
- 2009-08-28 AR ARP090103323A patent/AR073230A1/es active IP Right Grant
- 2009-08-28 PE PE2011000219A patent/PE20110393A1/es not_active Application Discontinuation
- 2009-08-28 KR KR1020117004579A patent/KR101648848B1/ko active IP Right Grant
- 2009-08-28 NZ NZ591446A patent/NZ591446A/xx not_active IP Right Cessation
- 2009-08-28 MX MX2011001918A patent/MX2011001918A/es active IP Right Grant
- 2009-08-28 CA CA2735497A patent/CA2735497C/en active Active
- 2009-08-28 JP JP2011524942A patent/JP5613669B2/ja active Active
- 2009-08-28 WO PCT/SE2009/050972 patent/WO2010024769A1/en active Application Filing
- 2009-08-28 EA EA201100267A patent/EA019093B1/ru not_active IP Right Cessation
- 2009-08-28 EP EP09810319.5A patent/EP2328891B1/en active Active
- 2009-08-28 CN CN201410653507.7A patent/CN104478862B/zh active Active
- 2009-08-28 CN CN201410655681.5A patent/CN104447710A/zh active Pending
- 2009-08-28 ES ES09810319.5T patent/ES2627769T3/es active Active
- 2009-08-28 BR BRPI0917147A patent/BRPI0917147B8/pt active IP Right Grant
- 2009-08-28 CN CN200980142788.7A patent/CN102197036B/zh active Active
-
2011
- 2011-02-10 IL IL211188A patent/IL211188A0/en unknown
- 2011-02-21 CO CO11020875A patent/CO6341628A2/es not_active Application Discontinuation
- 2011-02-25 CL CL2011000420A patent/CL2011000420A1/es unknown
- 2011-02-28 EC EC2011010850A patent/ECSP11010850A/es unknown
- 2011-03-28 ZA ZA2011/02284A patent/ZA201102284B/en unknown
-
2012
- 2012-06-04 US US13/487,349 patent/US8653274B2/en active Active
-
2014
- 2014-01-07 US US14/149,563 patent/US9309267B2/en active Active
-
2018
- 2018-11-12 AR ARP180103297A patent/AR114029A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114029A2 (es) | Compuestos adecuados como precursores de compuestos que son útiles para obtener imágenes de depósitos amiloides, usos y procesos | |
| UY30112A1 (es) | Nuevos benzotiazoles sustitidos por heteroarilo | |
| WO2009155017A3 (en) | Novel substituted azabenzoxazoles | |
| UY30419A1 (es) | Nuevos benzoxazoles heteroaril sustituidos | |
| ECSP099641A (es) | Nuevos benzotiofenos y benzofuranos sustituidos en la posición 2 con heteroarilo 709 | |
| MX2016016384A (es) | Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. | |
| BR112014012822A8 (pt) | Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2 | |
| MX2009007487A (es) | Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos. | |
| AR079641A1 (es) | Compuestos para el diagnostico por imagenes de la muerte de las celulas por apotosis | |
| UA113186C2 (xx) | Макроциклічні інгібітори lrrk2 кінази | |
| EA201490165A1 (ru) | Производные 1-арил-4-метил-[1,2,4]триазоло[4,3-a]хиноксалина | |
| PE20151375A1 (es) | Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion | |
| BRPI0515175A (pt) | método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer | |
| JP2012514007A5 (es) | ||
| AR071873A1 (es) | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida, un hidrato de la sal, un metodo de preparacion del compuesto, una composicion que lo comprende, un metodo para inhibir la actividad de la tirosina quinasa, un metodo para tratar una enfermedad y un proc | |
| AR063923A1 (es) | Sales del acido zoledronico, procesos de preparacion y composiciones | |
| BRPI1014595A2 (pt) | procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer | |
| WO2010051196A8 (en) | Novel substituted azabenzoxazoles | |
| IN2015DN00837A (es) | ||
| BRPI0808090A2 (pt) | Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente | |
| SG194759A1 (en) | Novel precursors of glutamate derivatives | |
| NZ591824A (en) | Butyrylcholinesterase ligands as diagnostic tools and treatment for deseases of the nervous system | |
| EA201070478A1 (ru) | Дифенилкарбоновые кислоты и их производные | |
| DOP2012000061A (es) | Utilizacion de derivados del indol como activadores de nurr-1, para la aplicacion en tratamientos de enfermedades como el parkinson | |
| TH112395A (th) | สารประกอบชนิดใหม่ที่เหมาะสมเป็นพรีเคอเซอร์ไปเป็นสารประกอบที่มีประโยชน์สำหรับการถ่ายภาพการสะสมอะมัยลอยด์ |